drugset / Trial / NCT02321527

Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients

NCT02321527 ↗

NaSingle-groupOpen-labelScreening

Summary

The goal of this clinical research is to learn if an ultrasound contrast agent called OPTISON (perflutren protein type A) is effective in finding sentinel lymph nodes before surgery. Contrast agents can help make ultrasound images more accurate. The sentinel lymph node is the first node that may be the target of cancer cells that spread from the tumor.

Timeline

Start
2015-07
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject perflutren protein type A Diagnostic / imaging agent 0.2 ml Subcutaneous
Subject perflutren protein type A Diagnostic / imaging agent 0.5 ml Subcutaneous

Indications